Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?
Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a three-center, randomized, double-blind, fixed dose study designed to assess the
efficacy, safety, and tolerability of a switch to vilazodone for sexual dysfunction
associated with use of a selective serotonin reuptake inhibitor (SSRI) and
serotonin-norepinephrine reuptake inhibitor (SNRI)compared to switching to sertraline in
patients with Major Depressive Disorder (MDD).
Vilazodone is a newly introduced, FDA approved antidepressant that is a combined serotonin
specific reuptake inhibitor and serotonin 1A receptor partial agonist. In contrast to the
SSRIs and SNRIs, appears to have low adverse effects on sexual functioning when compared to
placebo.